Oragenics Inc
OGEN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001174940
No open-market purchases or sales by Oragenics Inc insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $39.2K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Oragenics Inc changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 22 | 29 | +7 |
| Shares | 9.40M | 10.7M | +1.34M (+14.3%) |
| Value | $6.63M | $6.82M | +$188.0K (+2.8%) |
New holders (8)
Institutions that held Oragenics Inc at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 163,954 | $104.0K | 0.01% |
| Citadel Advisors LLC | 134,960 | $86.0K | 0.00% |
| Price T Rowe Associates Inc | 79,700 | $51.0K | 0.00% |
| Jane Street Group, LLC | 55,685 | $35.0K | 0.00% |
| Buckingham Strategic Wealth, LLC | 27,000 | $17.0K | 0.00% |
| HRT Financial LP | 17,250 | $10.0K | 0.00% |
| Newman Dignan & Sheerar, Inc. | 10,468 | $7.00K | 0.00% |
| Gerber Kawasaki Wealth & Investment Management | 1 | – | – |
Sold out (1)
Institutions that held Oragenics Inc at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Bank of America Corp | 46 | $0 |